Royalty Pharma Plc (RPRX) SEC Filing 8-K Material Event for the period ending Tuesday, May 17, 2022

Royalty Pharma Plc

CIK: 1802768 Ticker: RPRX

View differences made from one to another to evaluate Royalty Pharma Plc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Royalty Pharma Plc.


Assess how Royalty Pharma Plc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Royalty Pharma Plc's Definitive Proxy Statement (Form DEF 14A) filed after their 2022 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Material Contracts, Statements, Certifications & more

Royalty Pharma Plc provided additional information to their SEC Filing as exhibits

Ticker: RPRX
CIK: 1802768
Form Type: 8-K Corporate News
Accession Number: 0001193125-22-152478
Submitted to the SEC: Tue May 17 2022 7:37:14 AM EST
Accepted by the SEC: Tue May 17 2022
Period: Tuesday, May 17, 2022
Industry: Pharmaceutical Preparations
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: